Active Ingredient History
Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, extended-release formulation of desvenlafaxine for the treatment of major depressive disorder. Desvenlafaxine has been registered and is available on the market for the treatment of major depressive disorder in adults. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anhedonia (Phase 4)
Anxiety Disorders (Phase 4)
Breast Neoplasms (Phase 4)
Cardiovascular Diseases (Phase 2/Phase 3)
Cognition Disorders (Phase 4)
Cytochrome P-450 CYP2D6 (Phase 4)
Cytochrome P-450 CYP3A (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetic Neuropathies (Phase 3)
Dysthymic Disorder (Phase 4)
Fibromyalgia (Phase 2/Phase 3)
Healthy Volunteers (Phase 3)
Hot Flashes (Phase 4)
Medically Unexplained Symptoms (Phase 4)
Menopause (Phase 3)
Metabolism (Phase 1)
Methadone (Phase 4)
Neoplasms (Phase 2/Phase 3)
Neuroticism (Phase 4)
Opioid-Related Disorders (Phase 4)
Pain (Phase 3)
Pharmacokinetics (Phase 4)
Phobia, Social (Phase 4)
Prostatic Neoplasms (Phase 2/Phase 3)
Psychological Distress (Phase 4)
Sleep Wake Disorders (Phase 3)
Sports Medicine (Phase 1)
Vascular Depression (Phase 4)
Vasomotor System (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue